| 產(chǎn)品編號 | bs-41201R |
| 英文名稱 | Rabbit Anti-CD105 antibody |
| 中文名稱 | CD105抗體 |
| 別 名 | END; Endoglin; ENG; FLJ41744; HHT1; ORW; ORW1; Osler Rendu Weber syndrome 1; RP11 228B15.2; CD 105; CD105 antigen; EGLN_HUMAN; AI528660; AI662476; S-endoglin; SN6. |
| 研究領域 | 腫瘤 心血管 細胞生物 免疫學 信號轉(zhuǎn)導 干細胞 細胞膜受體 細胞表面分子 血管內(nèi)皮細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human |
| 產(chǎn)品應用 | IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=2ug/Test,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 70kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human CD105: 26-586/658 (C-6x His-Tag) <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a homodimeric transmembrane protein which is a major glycoprotein of the vascular endothelium. This protein is a component of the transforming growth factor beta receptor complex and it binds to the beta1 and beta3 peptides with high affinity. Mutations in this gene cause hereditary hemorrhagic telangiectasia, also known as Osler-Rendu-Weber syndrome 1, an autosomal dominant multisystemic vascular dysplasia. This gene may also be involved in preeclampsia and several types of cancer. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2013] Function: Major glycoprotein of vascular endothelium. May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Subunit: Homodimer that forms an heteromeric complex with the signaling receptors for transforming growth factor-beta: TGFBR1 and/or TGFBR2. It is able to bind TGF-beta 1, and 3 efficiently and TGF-beta 2 less efficiently. Interacts with TCTEX1D4. Interacts with ARRB2. Subcellular Location: Membrane; Single-pass type I membrane protein. Tissue Specificity: Endoglin is restricted to endothelial cells in all tissues except bone marrow. DISEASE: Defects in ENG are the cause of hereditary hemorrhagic telangiectasia type 1 (HHT1) [MIM:187300]; also known as Osler-Rendu-Weber syndrome 1 (ORW1). HHT1 is an autosomal dominant multisystemic vascular dysplasia, characterized by recurrent epistaxis, muco-cutaneous telangiectases, gastro-intestinal hemorrhage, and pulmonary (PAVM), cerebral (CAVM) and hepatic arteriovenous malformations; all secondary manifestations of the underlying vascular dysplasia. Although the first symptom of HHT1 in children is generally nose bleed, there is an important clinical heterogeneity. SWISS: P17813 Gene ID: 2022 Database links: Entrez Gene: 2022 Human Entrez Gene: 13805 Mouse Omim: 131195 Human SwissProt: P17813 Human SwissProt: Q63961 Mouse Unigene: 76753 Human Unigene: 225297 Mouse CD105（Endoglin）：CD105是一種分子量為180kDa的存在于細胞表面的同源二聚體跨膜糖蛋白，是TGF-β受體復合物的組成部分，是TGF-β的附屬受體，能與多種TGF-β超家族成員結合尤其與TGF-β1、TGF-β3有很高的親和力，調(diào)節(jié)TGF-βs與其受體結合而參與信號傳導，是內(nèi)皮細胞增殖相關膜抗原，在培養(yǎng)的高增殖活性內(nèi)皮細胞和許多惡性腫瘤組織血管內(nèi)皮細胞中高表達，參與血管生成，但其在血管生成調(diào)節(jié)中的作用機制尚未闡明。CD105基因定位于人9號染色體，是Ⅰ型遺傳性出血性毛細血管擴張癥的相關基因。CD105基因敲除小鼠胚胎因血管生成缺陷而于受精后平均11.5天死亡，故有學者認為，CD105可能與血管生成啟動有關，可用于標記腫瘤新生血管。 Endoglin是內(nèi)皮細胞表面與細胞增殖相關的膜抗原,也是轉(zhuǎn)化生長因子β超家族受體復合物成分之一。其具有調(diào)節(jié)內(nèi)皮細胞對TGF的反應、促內(nèi)皮細胞增殖和促血管形成等功能,與腫瘤血管的發(fā)生密切相關。近年來,Endoglin在腫瘤診斷、判斷預后和療效及抗腫瘤血管靶向治療等方面的作用得到重視。姬，2017.1.15； |
| 產(chǎn)品圖片 |
Paraformaldehyde-fixed, paraffin embedded (human liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CD105) Polyclonal Antibody, Unconjugated (bs-41201R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human liver carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CD105) Polyclonal Antibody, Unconjugated (bs-41201R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CD105) Polyclonal Antibody, Unconjugated (bs-41201R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CD105) Polyclonal Antibody, Unconjugated (bs-41201R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CD105) Polyclonal Antibody, Unconjugated (bs-41201R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Blank control:Hela.
Primary Antibody (green line): Rabbit Anti-CD105 antibody (bs-41201R)
Dilution: 2ug/Test;
Secondary Antibody : Goat anti-rabbit IgG-FITC
Dilution: 0.5ug/Test.
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
